IMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Juno Therapeutics Inc. and Advises Investors with Losses to Contact the Firm

LOS ANGELES--()--Lundin Law PC (http://lundinlawpc.com/) announces it is investigating claims against Juno Therapeutics Inc. (“Juno” or the “Company”) (Nasdaq: JUNO) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The investigation concerns whether the Company violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. Specifically, the investigation will focus on the July 7, 2016 disclosure that three patients died during a clinical trial for Juno’s chemotherapy drug, fludarabine. When this news was released, shares of Juno fell significantly.

Lundin Law PC was created by Brian Lundin, a securities litigator based in Los Angeles.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/

Contacts

Lundin Law PC
Brian Lundin, Esq.
Telephone: 888-713-1033
Facsimile: 888-713-1125
brian@lundinlawpc.com
http://lundinlawpc.com/